COVID-19-associated nausea and vomiting: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
(minor grammar edits) |
||
| (21 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
'''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]''' | {{SI}} | ||
''Main article:'' [[COVID-19]] | |||
'''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]''' | |||
'''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br> | '''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br> | ||
{{CMG}}; {{AE}} {{IF}} | {{CMG}}; {{AE}} {{IF}} | ||
| Line 9: | Line 11: | ||
==Overview== | ==Overview== | ||
SARS-CoV-2 mainly causes severe acute respiratory syndrome but may also present with gastrointestinal symptoms like diarrhea. It invades through the | SARS-CoV-2 mainly causes severe acute respiratory syndrome but may also present with [[gastrointestinal]] [[symptoms]] like [[diarrhea]]. It invades through the [[angiotensin-converting enzyme 2]] (ACE2) and the serine [[protease]] [[TMPRSS2]] [[receptors]] present abundantly not only in the [[lungs]] but also in the [[enterocytes]] of the [[small intestine]]. [[Nausea and vomiting]] are the less common [[gastrointestinal]] [[symptoms]] associated with COVID-19. [[Anorexia]] and [[diarrhea]] are more common. | ||
==Historical Perspective== | ==Historical Perspective== | ||
* The etiological agent is SARS-CoV-2, named for the similarity of its symptoms to those induced by the [[severe acute respiratory syndrome]], | * The etiological agent of COVID-19 infection is SARS-CoV-2, named for the similarity of its symptoms to those induced by the [[severe acute respiratory syndrome]], it is a [[virus]] identified as the cause of an outbreak of [[respiratory illness]] first detected in Wuhan, China.<ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/index.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref name="LuCui2020">{{cite journal|last1=Lu|first1=Jian|last2=Cui|first2=Jie|last3=Qian|first3=Zhaohui|last4=Wang|first4=Yirong|last5=Zhang|first5=Hong|last6=Duan|first6=Yuange|last7=Wu|first7=Xinkai|last8=Yao|first8=Xinmin|last9=Song|first9=Yuhe|last10=Li|first10=Xiang|last11=Wu|first11=Changcheng|last12=Tang|first12=Xiaolu|title=On the origin and continuing evolution of SARS-CoV-2|journal=National Science Review|year=2020|issn=2095-5138|doi=10.1093/nsr/nwaa036}}</ref> | ||
*The growing number of [[patients]] however, suggest that human-to-human transmission is actively occurring.<ref name="HuangWang2020">{{cite journal|last1=Huang|first1=Chaolin|last2=Wang|first2=Yeming|last3=Li|first3=Xingwang|last4=Ren|first4=Lili|last5=Zhao|first5=Jianping|last6=Hu|first6=Yi|last7=Zhang|first7=Li|last8=Fan|first8=Guohui|last9=Xu|first9=Jiuyang|last10=Gu|first10=Xiaoying|last11=Cheng|first11=Zhenshun|last12=Yu|first12=Ting|last13=Xia|first13=Jiaan|last14=Wei|first14=Yuan|last15=Wu|first15=Wenjuan|last16=Xie|first16=Xuelei|last17=Yin|first17=Wen|last18=Li|first18=Hui|last19=Liu|first19=Min|last20=Xiao|first20=Yan|last21=Gao|first21=Hong|last22=Guo|first22=Li|last23=Xie|first23=Jungang|last24=Wang|first24=Guangfa|last25=Jiang|first25=Rongmeng|last26=Gao|first26=Zhancheng|last27=Jin|first27=Qi|last28=Wang|first28=Jianwei|last29=Cao|first29=Bin|title=Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China|journal=The Lancet|volume=395|issue=10223|year=2020|pages=497–506|issn=01406736|doi=10.1016/S0140-6736(20)30183-5}}</ref><ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> | *The growing number of [[patients]] however, suggest that human-to-human [[transmission]] is actively occurring.<ref name="HuangWang2020">{{cite journal|last1=Huang|first1=Chaolin|last2=Wang|first2=Yeming|last3=Li|first3=Xingwang|last4=Ren|first4=Lili|last5=Zhao|first5=Jianping|last6=Hu|first6=Yi|last7=Zhang|first7=Li|last8=Fan|first8=Guohui|last9=Xu|first9=Jiuyang|last10=Gu|first10=Xiaoying|last11=Cheng|first11=Zhenshun|last12=Yu|first12=Ting|last13=Xia|first13=Jiaan|last14=Wei|first14=Yuan|last15=Wu|first15=Wenjuan|last16=Xie|first16=Xuelei|last17=Yin|first17=Wen|last18=Li|first18=Hui|last19=Liu|first19=Min|last20=Xiao|first20=Yan|last21=Gao|first21=Hong|last22=Guo|first22=Li|last23=Xie|first23=Jungang|last24=Wang|first24=Guangfa|last25=Jiang|first25=Rongmeng|last26=Gao|first26=Zhancheng|last27=Jin|first27=Qi|last28=Wang|first28=Jianwei|last29=Cao|first29=Bin|title=Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China|journal=The Lancet|volume=395|issue=10223|year=2020|pages=497–506|issn=01406736|doi=10.1016/S0140-6736(20)30183-5}}</ref><ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> | ||
*The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. | *The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. | ||
*On March 12, 2020, the [[World Health Organization]] declared the COVID-19 outbreak a [[pandemic]]. | *On March 12, 2020, the [[World Health Organization]] declared the COVID-19 outbreak a [[pandemic]]. | ||
| Line 22: | Line 24: | ||
==Pathophysiology== | ==Pathophysiology== | ||
*SARS-CoV-2 uses the [[Angiotensin-converting enzyme 2]] (ACE2) and the [[serine protease]] [[TMPRSS2]] receptors for cell entry. These receptors are | *SARS-CoV-2 uses the [[Angiotensin-converting enzyme 2]] (ACE2) and the [[serine protease]] [[TMPRSS2]] [[receptors]] for cell entry. | ||
*Entry of the virus causes disruption of the [[Enterocyte|enterocytes]] and may lead to inflammation and alteration of [[Intestine|intestinal]] [[permeability]]. | *These receptors are present abundantly not only in the [[Lung|lungs]] but also in the [[Enterocyte|enterocytes]] of the [[small intestine]]. | ||
* The gastrointestinal symptoms of COVID-19 are thought to arise due to the invasion of enterocytes.<ref name="pmid32376697">{{cite journal| author=Wahba L, Jain N, Fire AZ, Shoura MJ, Artiles KL, McCoy MJ | display-authors=etal| title=An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes. | journal=mSphere | year= 2020 | volume= 5 | issue= 3 | pages= | pmid=32376697 | doi=10.1128/mSphere.00160-20 | pmc=7203451 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32376697 }} </ref> | *Other sites of expression of the [[receptors]] in the gastrointestinal tract are-the upper [[esophagus]], [[liver]], and [[Colon (anatomy)|colon]].<ref name="pmid32278065">{{cite journal| author=D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L| title=Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. | journal=Clin Gastroenterol Hepatol | year= 2020 | volume= | issue= | pages= | pmid=32278065 | doi=10.1016/j.cgh.2020.04.001 | pmc=7141637 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32278065 }} </ref><ref name="pmid32102928">{{cite journal| author=Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z | display-authors=etal| title=Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. | journal=Gut | year= 2020 | volume= 69 | issue= 6 | pages= 1141-1143 | pmid=32102928 | doi=10.1136/gutjnl-2020-320832 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32102928 }} </ref> | ||
*Entry of the virus causes disruption of the [[Enterocyte|enterocytes]] and may lead to [[inflammation]] and alteration of [[Intestine|intestinal]] [[permeability]]. | |||
* The [[gastrointestinal]] [[symptoms]] of COVID-19 are thought to arise due to the invasion of [[enterocytes]].<ref name="pmid32376697">{{cite journal| author=Wahba L, Jain N, Fire AZ, Shoura MJ, Artiles KL, McCoy MJ | display-authors=etal| title=An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes. | journal=mSphere | year= 2020 | volume= 5 | issue= 3 | pages= | pmid=32376697 | doi=10.1128/mSphere.00160-20 | pmc=7203451 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32376697 }} </ref> | |||
==Causes== | ==Causes== | ||
Coronavirus disease 2019 (COVID-19) is caused by [[SARS-CoV-2|severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)]]. | |||
==Differentiating COVID-19 associated nausea and vomiting from other Diseases== | ==Differentiating COVID-19 associated nausea and vomiting from other Diseases== | ||
COVID-19 associated nausea and vomiting must be differentiated from other diseases that cause nausea and vomiting in a hospitalized patient | COVID-19 associated nausea and vomiting must be differentiated from other diseases that cause nausea and vomiting in a hospitalized patient inlclude: | ||
*[[Medication]]-induced [[nausea and vomiting]] | *[[Medication]]-induced [[nausea and vomiting]] | ||
*Food poisoning | *[[Food poisoning]] | ||
*Gastroenteritis | *Gastroenteritis ([[viral]] or [[bacterial]]) | ||
*[[Migraine]] | *[[Migraine]] | ||
*Indigestion | *Indigestion | ||
* | *[[Acute liver failure]] | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* | *The [[prevalence]] of nausea in COVID-19 patients is 26%. | ||
*The more common GI [[symptoms]] include [[anorexia]] (35% prevalence) and [[diarrhea]] (34% prevalence).<ref name="pmid32333911">{{cite journal| author=Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC | display-authors=etal| title=Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study. | journal=Gastroenterology | year= 2020 | volume= | issue= | pages= | pmid=32333911 | doi=10.1053/j.gastro.2020.04.045 | pmc=7195377 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32333911 }} </ref> | |||
* 16% of patients presented only with GI symptoms such as [[diarrhea]], [[nausea]], and [[vomiting]] without any respiratory symptoms. <ref name="pmid32205220">{{cite journal| author=Luo S, Zhang X, Xu H| title=Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). | journal=Clin Gastroenterol Hepatol | year= 2020 | volume= 18 | issue= 7 | pages= 1636-1637 | pmid=32205220 | doi=10.1016/j.cgh.2020.03.043 | pmc=7154217 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32205220 }} </ref> | |||
==Risk Factors== | ==Risk Factors== | ||
Some | Some [[Gastrointestinal|gastrointestina]]<nowiki/>l factors may predispose patients to infection with COVID-19. Common [[risk factors]] in the development of nausea and vomiting include:<ref name="pmid32425234">{{cite journal| author=Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD | display-authors=etal| title=Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry. | journal=Gastroenterology | year= 2020 | volume= | issue= | pages= | pmid=32425234 | doi=10.1053/j.gastro.2020.05.032 | pmc=7233252 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32425234 }} </ref> | ||
*[[Inflammatory bowel disease]] patients- due to use to [[glucocorticoids]], but not [[TNF-alpha|TNF-alpha inhibitors]] | *[[Inflammatory bowel disease]] patients- due to use to [[glucocorticoids]], but not [[TNF-alpha|TNF-alpha inhibitors]] | ||
| Line 57: | Line 57: | ||
==Screening== | ==Screening== | ||
* There is insufficient evidence to recommend routine | * There is insufficient evidence to recommend routine [[screening]]. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
* There is not enough data on the natural history, [[Complication (medicine)|complications]], and [[Prognosis|prognostic]] implications of n[[ausea and vomiting]] in [[COVID-19]]. | * There is not enough data on the natural history, [[Complication (medicine)|complications]], and [[Prognosis|prognostic]] implications of n[[ausea and vomiting]] in [[COVID-19]]. | ||
* To view natural history, complications, and prognosis of COVID-19, [[COVID-19 natural history, complications and prognosis|click here]]. | * To view [[Natural history, complications and prognosis template|natural history,]] [[complications]], and [[prognosis]] of COVID-19, [[COVID-19 natural history, complications and prognosis|click here]]. | ||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Study of Choice=== | ===Diagnostic Study of Choice=== | ||
* COVID-19 nausea and vomiting can be diagnosed based on the history of | * COVID-19 nausea and vomiting can be diagnosed based on the history of gastrointestinal symptoms like [[anorexia]], [[diarrhea]] and a positive [[Human feces|stool]] test for SARS-CoV-2 | ||
* There are no established criteria for the diagnosis of nausea and vomiting in COVID-19. | * There are no established criteria for the diagnosis of nausea and vomiting in COVID-19. | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
*According to a study by Redd et al, the prevalence of nausea in COVID-19 patients was 26%. <ref name="pmid32333911">{{cite journal| author=Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC | display-authors=etal| title=Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study. | journal=Gastroenterology | year= 2020 | volume= | issue= | pages= | pmid=32333911 | doi=10.1053/j.gastro.2020.04.045 | pmc=7195377 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32333911 }} </ref> | *According to a study by Redd et al, the [[prevalence]] of nausea in COVID-19 patients was 26%. The most common GI [[symptoms]] include [[anorexia]] and [[diarrhea]].<ref name="pmid32333911">{{cite journal| author=Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC | display-authors=etal| title=Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study. | journal=Gastroenterology | year= 2020 | volume= | issue= | pages= | pmid=32333911 | doi=10.1053/j.gastro.2020.04.045 | pmc=7195377 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32333911 }} </ref> | ||
* Another study by Luo et al reported that 16% of patients presented with GI symptoms like [[diarrhea]], [[nausea]], [[vomiting]] without any respiratory symptoms. <ref name="pmid32205220">{{cite journal| author=Luo S, Zhang X, Xu H| title=Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). | journal=Clin Gastroenterol Hepatol | year= 2020 | volume= 18 | issue= 7 | pages= 1636-1637 | pmid=32205220 | doi=10.1016/j.cgh.2020.03.043 | pmc=7154217 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32205220 }} </ref> | |||
* Another study by Luo et al reported that 16% of patients presented with GI symptoms like diarrhea, nausea, vomiting without any respiratory symptoms. <ref name="pmid32205220">{{cite journal| author=Luo S, Zhang X, Xu H| title=Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). | journal=Clin Gastroenterol Hepatol | year= 2020 | volume= 18 | issue= 7 | pages= 1636-1637 | pmid=32205220 | doi=10.1016/j.cgh.2020.03.043 | pmc=7154217 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32205220 }} </ref> | |||
===Physical Examination=== | ===Physical Examination=== | ||
Patients with gastrointestinal symptoms of COVID-19 usually appear listless. Physical examination of patients is non-specific. | Patients with [[gastrointestinal]] [[symptoms]] of COVID-19 usually appear listless. [[Physical examination]] of patients is non-specific. | ||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
* Infectious [[virions]] released from the GI tract can be monitored by real-time [[Reverse transcription polymerase chain reaction|reverse transcriptase polymerase chain reaction]] (rRT-PCR). | * Infectious [[virions]] released from the GI tract can be monitored by real-time [[Reverse transcription polymerase chain reaction|reverse transcriptase polymerase chain reaction]] (rRT-PCR). | ||
* A study by Xiao et al assessed the clinical significance of measuring [[SARS-CoV-2]] RNA in the feces. The fecal test remained positive until 12 days after the disease onset in patients with diarrhea.<ref name="pmid32142773">{{cite journal| author=Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H| title=Evidence for Gastrointestinal Infection of SARS-CoV-2. | journal=Gastroenterology | year= 2020 | volume= 158 | issue= 6 | pages= 1831-1833.e3 | pmid=32142773 | doi=10.1053/j.gastro.2020.02.055 | pmc=7130181 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32142773 }} </ref> | * A study by Xiao et al assessed the clinical significance of measuring [[SARS-CoV-2]] RNA in the feces. The fecal test remained positive until 12 days after the disease onset in patients with diarrhea.<ref name="pmid32142773">{{cite journal| author=Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H| title=Evidence for Gastrointestinal Infection of SARS-CoV-2. | journal=Gastroenterology | year= 2020 | volume= 158 | issue= 6 | pages= 1831-1833.e3 | pmid=32142773 | doi=10.1053/j.gastro.2020.02.055 | pmc=7130181 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32142773 }} </ref> | ||
* Notably, stool test for [[RNA|viral RNA]] remained positive despite negative respiratory tests. This suggests the possibility of gastrointestinal transmission via the fecal-oral route despite clearance from the respiratory tract. | * Notably, stool test for [[RNA|viral RNA]] remained positive despite negative respiratory tests. This suggests the possibility of [[gastrointestinal]] [[transmission]] via the [[fecal-oral route]] despite clearance from the respiratory tract. | ||
* It was recommended [[Transmission (medicine)|transmission]]-based precautions for hospitalized COVID-19 patients should be continued till the rRT-PCR for SARS-CoV-2 turns negative. | * It was recommended [[Transmission (medicine)|transmission]]-based precautions for hospitalized COVID-19 patients should be continued till the rRT-PCR for SARS-CoV-2 turns negative. | ||
===Electrocardiogram=== | ===Electrocardiogram=== | ||
There are no [[ECG]] findings associated with nausea and vomiting in COVID-19. | There are no [[ECG]] findings associated with nausea and vomiting in patients with COVID-19. | ||
===X-ray=== | ===X-ray=== | ||
| Line 118: | Line 112: | ||
===Primary Prevention=== | ===Primary Prevention=== | ||
===Prevention of transmission through gastrointenstinal tract=== | *Effective measures for the [[primary prevention]] of COVID-19 include:<ref name="urlHow to Protect Yourself & Others | CDC">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html |title=How to Protect Yourself & Others | CDC |format= |work= |accessdate=}}</ref> | ||
* Presence of the virus in the stool raises suspicion for [[ | **Frequent handwashing with soap and water for at least 20 seconds or using a [[Alcohol rub|alcohol based hand sanitizer]] with at least 60% alcohol | ||
* Appropriate | **Staying at least 6 feet (about 2 arms’ length) from people who do not live with you | ||
*Elective appointments and [[Endoscopy|endoscopies]] should be rescheduled and extreme care must be taken by health care professionals of the [[endoscopy]] units to avoid spreading the virus from one patient to another. <ref name=" | **Covering your mouth and nose with a cloth face cover when around others and covering sneezes and coughs | ||
* Patients listed for fecal microbiota transplantation and donors should be screened for the SARS-CoV-2. | **Cleaning and [[disinfect]]ing | ||
*There have been rigorous efforts in order to develop a [[vaccine]] for [[COVID-10|novel coronavirus]] and several vaccines are in the later phases of trials.<ref name="urlNIH clinical trial of investigational vaccine for COVID-19 begins | National Institutes of Health (NIH)">{{cite web |url=https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |title=NIH clinical trial of investigational vaccine for COVID-19 begins | National Institutes of Health (NIH) |format= |work= |accessdate=}}</ref> | |||
====Prevention of transmission through gastrointenstinal tract==== | |||
*Presence of the virus in the stool raises suspicion for [[Fecal-oral route|fecal-oral transmission]] of SARS-CoV-2. | |||
*Appropriate personal protective equipment (PPE) must be used while handling sources of contamination like feces. | |||
*[[Elective]] appointments and [[Endoscopy|endoscopies]] should be rescheduled and extreme care must be taken by health care professionals of the [[endoscopy]] units to avoid spreading the virus from one patient to another. <ref name="pmid321979572">{{cite journal| author=Ungaro RC, Sullivan T, Colombel JF, Patel G| title=What Should Gastroenterologists and Patients Know About COVID-19? | journal=Clin Gastroenterol Hepatol | year= 2020 | volume= 18 | issue= 7 | pages= 1409-1411 | pmid=32197957 | doi=10.1016/j.cgh.2020.03.020 | pmc=7156804 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32197957 }}</ref> | |||
*Patients listed for fecal [[Microbiome|microbiota]] transplantation and donors should be screened for the SARS-CoV-2. | |||
===Secondary prevention=== | |||
*Effective measures for the [[secondary prevention]] of COVID-19 include: | |||
**Use of [[personal protective equipment]] (PPE) by the personnel handling the fecal matter. | |||
**Screening of fecal [[Microbiome|microbiota]] [[transplant]] donors for [[COVID-19]] is also recommended.<ref name="pmid32240618">{{cite journal |vauthors=Green CA, Quraishi MN, Shabir S, Sharma N, Hansen R, Gaya DR, Hart AL, Loman NJ, Iqbal TH |title=Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward |journal=Lancet Gastroenterol Hepatol |volume=5 |issue=6 |pages=531 |date=June 2020 |pmid=32240618 |pmc=7225406 |doi=10.1016/S2468-1253(20)30089-3 |url=}}</ref> | |||
**[[Contact tracing]] helps reduce the spread of the disease.<ref name="urlContact Tracing for COVID-19 | CDC">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/contact-tracing.html |title=Contact Tracing for COVID-19 | CDC |format= |work= |accessdate=}}</ref> | |||
==References== | ==References== | ||
Latest revision as of 16:03, 27 July 2020
Main article: COVID-19
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ifrah Fatima, M.B.B.S[2]
Synonyms and keywords:
Overview
SARS-CoV-2 mainly causes severe acute respiratory syndrome but may also present with gastrointestinal symptoms like diarrhea. It invades through the angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 receptors present abundantly not only in the lungs but also in the enterocytes of the small intestine. Nausea and vomiting are the less common gastrointestinal symptoms associated with COVID-19. Anorexia and diarrhea are more common.
Historical Perspective
- The etiological agent of COVID-19 infection is SARS-CoV-2, named for the similarity of its symptoms to those induced by the severe acute respiratory syndrome, it is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.[1][2]
- The growing number of patients however, suggest that human-to-human transmission is actively occurring.[3][4]
- The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.
- On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.
Classification
There is no established system for the classification of nausea and vomiting in COVID-19.
Pathophysiology
- SARS-CoV-2 uses the Angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 receptors for cell entry.
- These receptors are present abundantly not only in the lungs but also in the enterocytes of the small intestine.
- Other sites of expression of the receptors in the gastrointestinal tract are-the upper esophagus, liver, and colon.[5][6]
- Entry of the virus causes disruption of the enterocytes and may lead to inflammation and alteration of intestinal permeability.
- The gastrointestinal symptoms of COVID-19 are thought to arise due to the invasion of enterocytes.[7]
Causes
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Differentiating COVID-19 associated nausea and vomiting from other Diseases
COVID-19 associated nausea and vomiting must be differentiated from other diseases that cause nausea and vomiting in a hospitalized patient inlclude:
- Medication-induced nausea and vomiting
- Food poisoning
- Gastroenteritis (viral or bacterial)
- Migraine
- Indigestion
- Acute liver failure
Epidemiology and Demographics
- The prevalence of nausea in COVID-19 patients is 26%.
- The more common GI symptoms include anorexia (35% prevalence) and diarrhea (34% prevalence).[8]
- 16% of patients presented only with GI symptoms such as diarrhea, nausea, and vomiting without any respiratory symptoms. [9]
Risk Factors
Some gastrointestinal factors may predispose patients to infection with COVID-19. Common risk factors in the development of nausea and vomiting include:[10]
- Inflammatory bowel disease patients- due to use to glucocorticoids, but not TNF-alpha inhibitors
- Increasing age
- Other comorbidities
- Use of glucocorticoids
Screening
- There is insufficient evidence to recommend routine screening.
Natural History, Complications, and Prognosis
- There is not enough data on the natural history, complications, and prognostic implications of nausea and vomiting in COVID-19.
- To view natural history, complications, and prognosis of COVID-19, click here.
Diagnosis
Diagnostic Study of Choice
- COVID-19 nausea and vomiting can be diagnosed based on the history of gastrointestinal symptoms like anorexia, diarrhea and a positive stool test for SARS-CoV-2
- There are no established criteria for the diagnosis of nausea and vomiting in COVID-19.
History and Symptoms
- According to a study by Redd et al, the prevalence of nausea in COVID-19 patients was 26%. The most common GI symptoms include anorexia and diarrhea.[8]
- Another study by Luo et al reported that 16% of patients presented with GI symptoms like diarrhea, nausea, vomiting without any respiratory symptoms. [9]
Physical Examination
Patients with gastrointestinal symptoms of COVID-19 usually appear listless. Physical examination of patients is non-specific.
Laboratory Findings
- Infectious virions released from the GI tract can be monitored by real-time reverse transcriptase polymerase chain reaction (rRT-PCR).
- A study by Xiao et al assessed the clinical significance of measuring SARS-CoV-2 RNA in the feces. The fecal test remained positive until 12 days after the disease onset in patients with diarrhea.[11]
- Notably, stool test for viral RNA remained positive despite negative respiratory tests. This suggests the possibility of gastrointestinal transmission via the fecal-oral route despite clearance from the respiratory tract.
- It was recommended transmission-based precautions for hospitalized COVID-19 patients should be continued till the rRT-PCR for SARS-CoV-2 turns negative.
Electrocardiogram
There are no ECG findings associated with nausea and vomiting in patients with COVID-19.
X-ray
- The chest X-ray findings in a suspected case of coronavirus infection can mimic the findings in pneumonia, which can include:[12]
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with nausea and vomiting in COVID-19.
CT scan
There are no CT scan findings associated with nausea and vomiting in COVID-19.
MRI
There are no MRI findings associated with nausea and vomiting in COVID-19.
Other Imaging Findings
There are no other imaging findings associated with nausea and vomiting in COVID-19.
Other Diagnostic Studies
There are no other diagnostic studies associated with nausea and vomiting in COVID-19.
Treatment
Medical Therapy
- Supportive management is the mainstay of treatment of nausea and vomiting.
- 5-HT3 antagonists such as ondansetron, granisetron, dolasetron, and palonosetron are commonly used for symptomatic relief.
- Rehydration, fluid repletion, and potassium monitoring are essential.
Primary Prevention
- Effective measures for the primary prevention of COVID-19 include:[13]
- Frequent handwashing with soap and water for at least 20 seconds or using a alcohol based hand sanitizer with at least 60% alcohol
- Staying at least 6 feet (about 2 arms’ length) from people who do not live with you
- Covering your mouth and nose with a cloth face cover when around others and covering sneezes and coughs
- Cleaning and disinfecting
- There have been rigorous efforts in order to develop a vaccine for novel coronavirus and several vaccines are in the later phases of trials.[14]
Prevention of transmission through gastrointenstinal tract
- Presence of the virus in the stool raises suspicion for fecal-oral transmission of SARS-CoV-2.
- Appropriate personal protective equipment (PPE) must be used while handling sources of contamination like feces.
- Elective appointments and endoscopies should be rescheduled and extreme care must be taken by health care professionals of the endoscopy units to avoid spreading the virus from one patient to another. [15]
- Patients listed for fecal microbiota transplantation and donors should be screened for the SARS-CoV-2.
Secondary prevention
- Effective measures for the secondary prevention of COVID-19 include:
- Use of personal protective equipment (PPE) by the personnel handling the fecal matter.
- Screening of fecal microbiota transplant donors for COVID-19 is also recommended.[16]
- Contact tracing helps reduce the spread of the disease.[17]
References
- ↑ https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty
|title=(help) - ↑ Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.
- ↑ Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
- ↑ https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html. Missing or empty
|title=(help) - ↑ D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L (2020). "Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management". Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2020.04.001. PMC 7141637 Check
|pmc=value (help). PMID 32278065 Check|pmid=value (help). - ↑ Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z; et al. (2020). "Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus". Gut. 69 (6): 1141–1143. doi:10.1136/gutjnl-2020-320832. PMID 32102928 Check
|pmid=value (help). - ↑ Wahba L, Jain N, Fire AZ, Shoura MJ, Artiles KL, McCoy MJ; et al. (2020). "An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes". mSphere. 5 (3). doi:10.1128/mSphere.00160-20. PMC 7203451 Check
|pmc=value (help). PMID 32376697 Check|pmid=value (help). - ↑ 8.0 8.1 Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC; et al. (2020). "Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study". Gastroenterology. doi:10.1053/j.gastro.2020.04.045. PMC 7195377 Check
|pmc=value (help). PMID 32333911 Check|pmid=value (help). - ↑ 9.0 9.1 Luo S, Zhang X, Xu H (2020). "Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)". Clin Gastroenterol Hepatol. 18 (7): 1636–1637. doi:10.1016/j.cgh.2020.03.043. PMC 7154217 Check
|pmc=value (help). PMID 32205220 Check|pmid=value (help). - ↑ Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD; et al. (2020). "Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry". Gastroenterology. doi:10.1053/j.gastro.2020.05.032. PMC 7233252 Check
|pmc=value (help). PMID 32425234 Check|pmid=value (help). - ↑ Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020). "Evidence for Gastrointestinal Infection of SARS-CoV-2". Gastroenterology. 158 (6): 1831–1833.e3. doi:10.1053/j.gastro.2020.02.055. PMC 7130181 Check
|pmc=value (help). PMID 32142773 Check|pmid=value (help). - ↑ Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (January 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. doi:10.1016/S0140-6736(20)30183-5. PMID 31986264.
- ↑ "How to Protect Yourself & Others | CDC".
- ↑ "NIH clinical trial of investigational vaccine for COVID-19 begins | National Institutes of Health (NIH)".
- ↑ Ungaro RC, Sullivan T, Colombel JF, Patel G (2020). "What Should Gastroenterologists and Patients Know About COVID-19?". Clin Gastroenterol Hepatol. 18 (7): 1409–1411. doi:10.1016/j.cgh.2020.03.020. PMC 7156804 Check
|pmc=value (help). PMID 32197957 Check|pmid=value (help). - ↑ Green CA, Quraishi MN, Shabir S, Sharma N, Hansen R, Gaya DR, Hart AL, Loman NJ, Iqbal TH (June 2020). "Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward". Lancet Gastroenterol Hepatol. 5 (6): 531. doi:10.1016/S2468-1253(20)30089-3. PMC 7225406 Check
|pmc=value (help). PMID 32240618 Check|pmid=value (help). - ↑ "Contact Tracing for COVID-19 | CDC".